GlassScriptPhysician profile
Evelyn Onaga
NPI 1194495960
$4,787.11
in general payments reported to CMS, 2019-2025
25 companies · $1,919 in 2025
The $1,919 reported for 2025 was more than what 97% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
See the full distribution for Critical Care Medicine (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $435 · 2022: $187 · 2023: $899 · 2024: $1,346 · 2025: $1,919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,164.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $641.27 | 2022-2025 | Uplizna |
| Abbvie INC. | $472.72 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $362.42 | 2023-2025 | Opdivo, Pomalyst |
| Celgene Corporation | $329.41 | 2021 | |
| Genzyme Corporation | $294.58 | 2023 | |
| Argenx US, INC. | $284.18 | 2022-2025 | Vyvgart |
| Merck Sharp & Dohme LLC | $248.80 | 2025 | Zerbaxa |
| Pharmacosmos Therapeutics INC. | $247.44 | 2025 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $144.96 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $141.21 | 2023 | Calquence |
| Sobi, INC | $125.00 | 2024 | |
| Horizon Therapeutics Plc | $124.20 | 2023 | Uplizna |
| Alcresta Therapeutics, INC. | $124.08 | 2025 | Relizorb |
| Actelion Pharmaceuticals US, INC. | $123.95 | 2025 | Uptravi, Opsumit |
| Fresenius Kabi USA, LLC | $122.54 | 2025 | Smoflipid |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $121.82 | 2024 | Giapreza |
| Philips North America LLC | $117.84 | 2024 | (1439) Hpm Undivided |
| Tg Therapeutics, INC. | $111.80 | 2025 | |
| Mallinckrodt Hospital Products INC. | $107.73 | 2025 | Terlivaz |
| Genentech USA, INC. | $105.98 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $99.42 | 2025 | Arctic Sun 5000 |
| Gilead Sciences, INC. | $87.17 | 2025 | Epclusa |
| Ucb, INC. | $85.67 | 2024 | Rystiggo |
| Biogen, INC. | $85.66 | 2023 | Tysabri |
| Btg International INC. | $77.26 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evelyn Onaga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.